New Mobile Cardiac Outpatient Telemetry system from CardioNet

CardioNet, Inc. (NASDAQ:BEAT) today announced the availability of new, innovative clinical and reporting enhancements to the Company’s existing Mobile Cardiac Outpatient Telemetry™ (MCOT™) service. These enhancements allow physicians to access more in depth data to better diagnose atrial fibrillation, heart pauses, and ventricular tachycardia (a potentially dangerous fast heartbeat).

“CardioNet remains dedicated to meeting the needs of cardiologists and electrophysiologists and to delivering innovative tools that allow these physicians to make more accurate diagnostic decisions,” said Randy Thurman, CardioNet Chairman, President and CEO. “The new enhancements sustain MCOT’s diagnostic and reporting superiority in monitoring cardiac events.”

The new clinical indicators are important for monitoring patients who are suffering from cardiac events, both symptomatic and asymptomatic. These indicators become even more important when used in combination with SomNet™, CardioNet’s program for identifying a sleep disorder indicator. In the case of SomNet, a more definitive diagnosis can be made as to the relationship of arrhythmias to sleep disorders. With this latest enhancement to the CardioNet MCOT service, doctors can see the frequency, time, and duration of cardiac events within every 24 hours.

“The new reports made possible through these enhancements are extremely relevant for treating patients,” said Dr. Peter Kowey, CardioNet Medical Director, and Chief of the Division Of Cardiovascular Disease for the Main Line Health System. “These enhancements deepen our understanding of the individual cardiac events for each patient and minimizes the likelihood of making an inaccurate diagnosis and treatment decision.”

http://www.cardionet.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
LSUHealthNO to examine effectiveness of novel drug designed for heart muscle regeneration